Director/PDMR Shareholding

RNS Number : 3208M

Oxford BioDynamics PLC

20 May 2022

 

20 May 2022

Oxford BioDynamics Plc

( "OBD" or the "Company" and, together with its subsidiaries, the "Group")

PDMR Dealing

Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Matthew Wakefield, the Group's Non-Executive Chairman, has purchased 25,000 Ordinary Shares of 1 pence each ("shares") at an average price of 17.4p per share.

Following this transaction, Matthew Wakefield is interested in 650,000 shares, representing 0.65% of the Company's current issued share capital.

The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further details:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Matthew Wakefield
2	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1 pence each ISIN:  GB00BD5H8572
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 0.174 25,000
d)	Aggregated information - Aggregated volume - Price	Price Volume 0.174 25,000
e)	Dates of the transactions	20 May 2022
f)	Place of the transaction	London Stock Exchange (XLON)

For further details please contact:

Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO	[phone]
Shore Capital Nominated Adviser and Broker Stephane Auton John More	[phone]
Instinctif Partners	Tel: [phone]
Melanie Toyne-Sewell / Jonjo Cordey	[e-mail]

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is  EpiSwitch® CiRT  (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test,  EpiSwitch ®   CST  (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery,  EpiSwitch® Explorer Array Kit . 

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website,  www.oxfordbiodynamics.com , or follow on  Twitter  or  LinkedIn .

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

 

END

 

 

DSHFLFSSEDIIFIF